Skip to main content
Premium Trial:

Request an Annual Quote

Genome Quebec Funds VIA's PGx Study in Clinical Trials for ACS Drug

NEW YORK (GenomeWeb News) - VIA Pharmaceuticals said today that it has secured funding from Genome Quebec to perform a pharmacogenomics sub-study as part of clinical trials for its lead candidate for acute coronary syndrome.
 
VIA said it will collaborate with the Montreal Heart Institute to perform genomics and proteomics studies and develop a genotyping panel it could use in Phase II clinical trials for its ACS drug VIA-2291.
 
VIA, a San Francisco-based small-molecule drug developer, estimated that the program will cost around $5 million. The company will provide around $2.4 million in funding for the ACS clinical trial, and around $200,000 for costs related to the pharmacogenomics sub-study. Genome Quebec and other companies will provide the balance of the funding, the company said.
 
The project will focus on development of a 5 lipoxygenase genotyping panel and an ADME/tox panel for VIA-2291, VIA said.
 
"We believe that this sub-study will generate important information on the pharmacogenomics of our study patients, and will provide additional insight into the role we believe VIA-2291 will play in reducing vascular inflammation in ACS patients with atherosclerosis," VIA CEO Lawrence Cohen said in a statement.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.